Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice

Article Abstract:

Research has been conducted on the diabetes development in a non-obese mice. Results demonstrate that alpha-galactosylceramide prevents diabetes in the wild-type but not I-like protein-deficient non-obese mice.

Author: Scherer, David C., Hong, Seokmann, Wilson, Michael T., Serizawa, Isao, Wu, Lan, Singh, Nagendra, Naidenko, Olga V., Miura, Toru, Haba, Tomoku, Wei, Jie, Kronenberg, Mitchell, Koezuka, Yasuhiko, Kaer, Luc van
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2001
Diabetes, Diabetes mellitus, Autoimmune diseases, Ligands, Ligands (Chemistry)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes

Article Abstract:

Research has been conducted on the type 1 diabetes in non-obese diabetic mice. Results indicate that alpha-galactosylceramide treatment protects female non-obese diabetic mice from type 1 diabetes and prolongs the pancreatic islets survival.

Author: Naidenko, Olga V., Kronenberg, Mitchell, Koezuka, Yasuhiko, Sharif, Shayan, Arreaza, Guillermo A., Zucker, Peter, Mi, Qing-Sheng, Delovitch, Terry L., Gombert, Jean-Marc, Leite-de-Moraez, Maria, Gouarin, Christine, Zhu, Ren, Hameg, Agathe, Nakayama, Toshinori, Taniguchi, Masaru, Lepault, Francoise, Lehuen, Agnes, Bach, Jean-Francois, Herbelin, Andre
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2001
Canada, France, Research, Type 1 diabetes, Islands of Langerhans, Islets of Langerhans

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity

Article Abstract:

Research shows that the development of airway hyperreactivity requires the activation of pulmonary natural killer T cells, which produce interleukin-4 and interleukin-13. Data indicate that the pulmonary natural killer T cells may aid the lungs leading to type 2 T-helper responses, which mediate the development of airway hyperreactivity and asthma.

Author: Grusby, Michael J., Kronenberg, Mitchell, Nakayama, Toshinori, Taniguchi, Masaru, Akbari, Omid, Stock, Philippe, Meyer, Everett, Sidobre, Stephane, DeKruyff, Rosemarie H., Umtsu, Dale T.
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2003
Biological Product (except Diagnostic) Manufacturing, Biological products exc. diagnostic, Interleukin, Asthma, Circulatory system, Interleukins, Cardiopulmonary system, Respiratory system, Killer cells, Respiratory organs

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Psychological aspects, United States, Analysis, Japan, Causes of, Physiological aspects, Obesity, Medical research, T cells
Similar abstracts:
  • Abstracts: Induction of premature labor and delivery by allergic reaction and prevention by histamine H(sub 1) receptor antagonist
  • Abstracts: A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease
  • Abstracts: 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity
  • Abstracts: Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. CD4 (super)+ T-cell-epitope mutant virus selected "in vivo"
  • Abstracts: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. Intensive versus moderate lipid lowering with statins after acute coronary syndromes
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.